Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMND Clearmind Medicine	$1.01 +1.2%	$0.96	$0.80 ▼ $2.18	$4.29M	0.96	476,703 shs	47,401 shs
EVFM Evofem Biosciences	$0.01 +3.3%	$0.01	$0.01 ▼ $0.02	$1.10M	-0.99	401,287 shs	152,800 shs
GLTO Galecto	$3.28 -3.0%	$3.44	$2.01 ▼ $15.13	$4.33M	1.35	123,829 shs	7,459 shs
INDP Indaptus Therapeutics	$7.86 +0.8%	$10.07	$6.65 ▼ $58.24	$4.47M	1.14	104,172 shs	2,443 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMND Clearmind Medicine	+1.32%	+2.04%	+5.20%	+2.04%	-15.25%
EVFM Evofem Biosciences	-6.25%	-2.17%	-3.23%	+7.14%	-7.22%
GLTO Galecto	-1.51%	-1.51%	-5.59%	+19.32%	-74.39%
INDP Indaptus Therapeutics	+8.79%	+6.85%	-35.00%	-36.69%	-83.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMND Clearmind Medicine	0.4705 of 5 stars	0.0	2.0	0.0	2.6	1.7	0.0
EVFM Evofem Biosciences	0.7349 of 5 stars	0.0	3.0	4.8	0.6	0.0	0.0
GLTO Galecto	3.0908 of 5 stars	3.5	3.0	0.0	2.5	1.7	1.3
INDP Indaptus Therapeutics	2.9589 of 5 stars	3.5	5.0	0.0	0.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMND Clearmind Medicine	0.00	N/A	N/A	N/A
EVFM Evofem Biosciences	0.00	N/A	N/A	N/A
GLTO Galecto	3.00	Buy	$10.00	207.22% Upside
INDP Indaptus Therapeutics	3.00	Buy	$238.00	2,933.78% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	$0.73 per share	N/A
EVFM Evofem Biosciences	$11.39M	0.09	N/A	N/A	($2.64) per share	0.00
GLTO Galecto	N/A	N/A	N/A	N/A	$10.99 per share	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$10.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMND Clearmind Medicine	-$5.26M	-$1.10	N/A	∞	N/A	N/A	-164.79%	-71.12%	9/15/2025 (Estimated)
EVFM Evofem Biosciences	$52.98M	-$0.05	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
GLTO Galecto	-$21.44M	-$13.13	N/A	N/A	N/A	N/A	-115.70%	-95.42%	N/A
INDP Indaptus Therapeutics	-$15.02M	-$41.74	N/A	N/A	N/A	N/A	-333.02%	-216.36%	N/A

Latest EVFM, GLTO, INDP, and CMND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	GLTO Galecto	N/A	-$2.60	N/A	-$2.60	N/A	N/A
6/12/2025	Q2 2025	CMND Clearmind Medicine	N/A	-$0.16	N/A	-$0.16	N/A	N/A
5/14/2025	Q1 2025	INDP Indaptus Therapeutics	-$11.48	-$8.96	+$2.52	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
GLTO Galecto	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMND Clearmind Medicine	N/A	1.74	1.74
EVFM Evofem Biosciences	N/A	0.11	0.09
GLTO Galecto	N/A	4.96	4.96
INDP Indaptus Therapeutics	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMND Clearmind Medicine	96.05%
EVFM Evofem Biosciences	0.22%
GLTO Galecto	14.20%
INDP Indaptus Therapeutics	7.06%

Insider Ownership

Company	Insider Ownership
CMND Clearmind Medicine	N/A
EVFM Evofem Biosciences	0.21%
GLTO Galecto	10.80%
INDP Indaptus Therapeutics	20.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMND Clearmind Medicine	N/A	4.27 million	N/A	Not Optionable
EVFM Evofem Biosciences	120	118.66 million	113.12 million	Not Optionable
GLTO Galecto	40	1.32 million	1.18 million	Optionable
INDP Indaptus Therapeutics	6	570,000	454,000	Not Optionable

EVFM, GLTO, INDP, and CMND Headlines

Recent News About These Companies

Indaptus Therapeutics (INDP) to Release Earnings on Monday

August 10 at 2:43 AM | americanbankingnews.com

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

July 1, 2025 | globenewswire.com

Indaptus Therapeutics Announces Reverse Stock Split - FinanzNachrichten.de

June 26, 2025 | finanznachrichten.de

Indaptus Therapeutics, Inc. Announces One-for-Twenty-Eight Reverse Stock Split to Enhance Nasdaq Compliance and Attract Investors

June 26, 2025 | nasdaq.com

Indaptus Therapeutics Announces Reverse Stock Split

June 25, 2025 | globenewswire.com

Indaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding Round

June 13, 2025 | quiverquant.comQ

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

June 13, 2025 | globenewswire.com

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

June 2, 2025 | globenewswire.com

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025 | globenewswire.com

Indaptus Therapeutics, Inc. Common Stock

March 30, 2025 | fxempire.comF

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

March 25, 2025 | globenewswire.com

Indaptus Therapeutics reports new data on Phase 1 trial of Decoy20

March 21, 2025 | markets.businessinsider.com

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

March 20, 2025 | globenewswire.com

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

March 18, 2025 | globenewswire.com

Indaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last year

March 13, 2025 | markets.businessinsider.com

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

March 13, 2025 | globenewswire.com

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

March 12, 2025 | globenewswire.com

Indaptus Therapeutics expands patent portfolio in China, Japan, Israel

March 4, 2025 | markets.businessinsider.com

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

March 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM, GLTO, INDP, and CMND Company Descriptions

Clearmind Medicine NASDAQ:CMND

$1.01 +0.01 (+1.20%)

As of 03:16 PM Eastern

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Evofem Biosciences NASDAQ:EVFM

$0.0093 +0.00 (+3.33%)

As of 02:46 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Galecto NASDAQ:GLTO

$3.28 -0.10 (-2.96%)

As of 03:16 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Indaptus Therapeutics NASDAQ:INDP

$7.86 +0.06 (+0.77%)

As of 03:17 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time